Zeynep ORUÇ, Senar EBINC, Halis YERLİKAYA, Muhammet Ali KAPLAN, Zuhat URAKÇI, Mehmet KÜÇÜKÖNER, İdris ORUÇ, Hüseyin BÜYÜKBAYRAM, Sadullah GİRGİN, Abdurrahman IŞIKDOĞAN

Erkeklerde Meme Kanseri ve Klinik Özellikleri: Tek Merkez Deneyimi

Giriş: Erkek meme kanseri, kadın meme kanserinden farklı kliniko-patolojik ve immunohistokimyasal özellikler gösteren ve kadın meme kanserine oranla nadir görülen bir hastalıktır.Yöntemler: 2007-2019 tarihleri arasında Dicle Üniversitesi Tıp Fakültesi Tıbbi Onkoloji bölümünde takip ve tedavi edilen erkek meme kanserli hastaların kliniko-patolojik özellikleri, aldıkları tedaviler ve tedavi sonuçları retrospektif olarak incelendi.Bulgular: İnvaziv meme karsinomu tanılı 50 erkek hasta analiz edildi. Ortalama yaş 63,7 yıl (34-88) idi. Kırk dört (%88) hasta lokal ileri ve metastatik hastalığa sahipti. Hastaların 38’ine (%76) mastektomi uygulanmıştı. En sık görülen histolojik tip %90 oran ile invaziv duktal karsinom idi. Hastaların 40’ında (%80) östrojen reseptör, 41’inde (%82) progesteron reseptör pozitifliği mevcuttu. HER2 overekspresyonu 11(%22) hastada izlenmişti. Küratif cerrahi sonrası hastaların 30’u (%60) adjuvan kemoterapi, 34’ü (%68) adjuvan endokrin tedavi almıştı. Medyan takip süresi 54,5 aydı ( 1-299 ay). Evre I-III olan 39 hastanın 15’inde (%38) remisyonda izlemde iken nüks gelişmişti. Evre I ve II meme kanserli hastalarda medyan sağkalım süresine ulaşılmamışken, evre III ve IV hastalarda medyan sağkalım süresi sırası ile 84 ve 36 aydı. Tek değişkenli ve çok değişkenli analizde sadece aksiller lenf nodu tutulumu, tümör boyutu ve hastalığın evresi sağkalım ile istatistiksel olarak anlamlı şekilde ilişkiliydi.Sonuç: Çalışmamız erkek meme kanserli hastalarda aksiller lenf nodu metastazının, tümör boyutunun ve hastalık evresinin sağkalımı predikte eden önemli prognostik faktörler olduğunu göstermiştir.

Breast Cancer In Men And Clinical Features: One Center Experience

Objective: Male breast cancer is a rare disease,which has different clinicopathological and immunohistochemical features from female breast cancer. Methods: We retrospectively analyzed the clinicopathological characteristics, treatment patterns, and outcomes of mBCs treated and followed in Dicle University Faculty of Medicine,Department of Medical Oncology,between 2007 and 2019. Results: Fifty male patients with breast invasive carcinoma were analyzed. Mean age was 63,7 years (range:34-88 years).Forty four patients (88%) had locally advanced and metastatic disease. Mastectomy was performed in 38 (76%) of the patients. The most frequent histology was invazive ductal carcinoma (90%). Estrogen receptors were positive in 40 patients (80%), and progesterone receptors were positive in 41 patients (82%). HER-2 was overexpressed in 11 of 50 patients (22%). After curative surgery, 30 (60%) patients had received adjuvant chemotherapy and 34 (68%) patients had received endocrine therapy. Median follow-up was 54.5 months (range: 1-299 months). Fifteen of 39 patients (38%) with stage 1-3 disease experienced recurrent disease. While median overall survival durations were not reached in patients with stage 1 and 2 breast cancer, median overall survival in stage 3 and 4 was 84 and 36 months, respectively. İn univariate and multivariate analysis, only positive axillary lymph node, tumor size and stage were significantly associated with survival. Conclusion: Our study showed that axillary lymph node metastasis, tumor size and stage in male breast cancer patients are important prognostic factors that predict survival.

PDF

___

1.White J, Kearins O, Dodwell D, et al. Male breastcarcinoma: Increased awareness needed. BreastCancer Res 2011; 13: 219.
2.SEER*Explorer: an interactive website for SEERcancer statistics. http://www.seer.cancer.gov/explo rer/. Accessed 16 July 2018
3. Speirs V, Shaaban AM. The rising incidence of malebreast cancer. Breast Cancer Res Treat 2009; 115:429–30.
4.Gucalp A, Traina TA, Eisner JR, et al..Male breastcancer: a disease distinct from female breastcancer.Breast Cancer Res Treat. 2019 Jan; 173: 37-48.doi: 10.1007/s10549-018-4921-9. Epub 2018Sep 28.
5.Sevimli TS, Sevimli M, Özçelik N.Meme kanserindeprotein ekspresyon değişimleri ve önemi.Dicle TipDergisi (2013): 161-8.
6.Pritzlaff M, Summerour P, McFarland R, et al. Malebreast cancer in a multi-gene panel testing cohort:insights and unexpected results. Breast CancerResearch and Treatment.2017;161(3), 575–86.
7.Howlader N, Noone A, Krapcho M, et al.SEERCancer statistics review.2017, National CancerInstitute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016SEER data submission, posted to the SEER web site.Accessed 8/7/2017.
8.Leon-Ferre RA, Giridhar KV, Hieken TJ, MutterRW, Couch FJ. A contemporary review of male breastcancer: current evidence and unanswered questions. Cancer Metastasis Rev. 2018 Dec;37(4):599-614. doi: 10.1007/s10555-018-9761-x.
9.Fentiman IS, Fourquet A, Hortobagyi GN. Malebreast cancer. Lancet. 2006; 367: 595-604.
10.Masci G, Caruso M, Caruso F, et al.Clinicopathological and ImmunohistochemicalCharacteristics in Male Breast Cancer: ARetrospective Case Series. Oncologist. 2015 Jun; 20:586-92. doi: 10.1634/theoncologist.2014-0243.Epub 2015 May 6.
11.Ozmen V. Breast cancer in Turkey: clinical andhistopathological characteristics ( Anaysis of 13,240Patients ). J Breast Health 2014; 10: 98-105.
12.Hill TD, Khamis HJ, Tyczynski JE, Berkel HJ.Comparison of male and female breast cancerincidence trends, tumor characteristics, andsurvival. Ann Epidemiol. 2005; 15: 773-80.
13.Soliman M, Hetnał M. Male breast cancer: aclinicopathological study of an Egyptian population(Alexandria experience). Contemp Oncol (Pozn).2016; 20: 335-40. doi: 10.5114/wo.2016.61855.Epub 2016 Sep 5.
14.Borgen PI, Wong GY, Vlamis V, et al. Currentmanagement of male breast cancer. A review of 104cases. Ann Surg. 1992 May; 215: 451-7; discussion457-9.
15.Vermeulen M. A., Slaets L., Cardoso F., et al.Pathological characterisation of male breast cancer:results of the EORTC 10085/TBCRC/BIG/NABCGinternational male breast Cancer program.EuropeanJournal of Cancer.2017; 82, 219–227.https://doi.org/10.1016/j.ejca.2017.01.034.
16.Arslan UY, Oksuzoglu B, Ozdemir N, etal.Outcome of non-metastatic male breast cancer:118 patients. Med Oncol 2012;29: 554–60
17.Anderson WF, Jatoi I, Tse J, Rosenberg PS. Malebreast cancer: a population-based comparison withfemale breast cancer.J Clin Oncol 2010; 28: 232–9.
18.Giordano SH, Cohen DS, Buzdar AU, Perkins G,Hortobagyi GN. Breast carcinoma in men: apopulation-based study. Cancer. 2004; 101: 51-7.
19.Nahleh ZA, Srikantiah R, Safa M, et al. Male breastcancer in the veterans affairs population: acomparative analysis. Cancer. 2007; 109: 1471-7.
20.Xie J, Ying YY, Xu B, et al. Metastasis pattern andprognosis of male breast cancer patients in US: apopulation-based study from SEER database. TherAdv Med Oncol. 2019 Nov 16;11:1758835919889003. doi: 10.1177/1758835919889003. eCollection 2019.
21.Yu XF, Yang HJ, Yu Y, Zou DH, Miao LL. APrognostic Analysis of Male Breast Cancer (MBC)Compared with Post-Menopausal Female BreastCancer (FBC). PLoS One. 2015; 10: e0136670.
22.Cardoso F, Bartlett JMS, Slaets L, etal.Characterization of male breast cancer: results ofthe EORTC 10085/TBCRC/BIG/NABCGInternational Male Breast Cancer Program. AnnOncol 2018;29: 405–17
23.Yadav S, Karam D, Bin Riaz I, et al. Male breastcancer in the United States: Treatment patterns andprognostic factors in the 21st century.Cancer. 2020Jan 1; 126: 26-36. doi: 10.1002/cncr.32472. Epub2019 Oct 7.
24.Ruddy KJ, Winer EP. Male breast cancer: Riskfactors, biology, diagnosis, treatment, andsurvivorship. Ann Oncol 2013; 24: 1434–43.
25.Korde LA, Zujewski JA, Kamin L et al.Multidisciplinary meeting on male breast cancer:Summary and research recommendations. J ClinOncol 2010; 28: 2114–22.
26.Hong JH, Ha KS, Jung YH, et al. Clinical Featuresof Male Breast Cancer: Experiences from SevenInstitutions Over 20 Years. Cancer Res Treat. 2016Oct; 48: 1389-1398. Epub 2016 Apr 11.
27.Darkeh MHSE, Azavedo E.Male breast cancerclinical features, risk factors, and current diagnosticand therapeutic approaches. Int J Clin Med 2014;5:1068–86
28.Giordano SH.Breast Cancer in Men. N Engl J Med.2018; 378: 2311-20.